The macrophage activation marker CD163 is associated with IL28B genotype and hepatic inflammation in chronic hepatitis C virus infected patients

Journal of Viral Hepatitis

Volumn 23, Issue 4, 2016, Pages 267-273

  Dultz, G ^a   Gerber, L ^a   Zeuzem, S ^a   Sarrazin, C ^a   Waidmann, O ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

HCV; IL28B; Kupffer cells; macrophage activation; sCD163

Indexed keywords

CD163 ANTIGEN; INTERLEUKIN 28B; PEGINTERFERON; RIBAVIRIN; ANTIVIRUS AGENT; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; LEUKOCYTE ANTIGEN;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; IL28B GENE; INFLAMMATION; KUPFFER CELL; LIVER FIBROSIS; LIVER HISTOLOGY; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SUSTAINED VIROLOGIC RESPONSE; TREATMENT RESPONSE; BLOOD; CYTOCHEMISTRY; GENETICS; HEPATITIS C, CHRONIC; MIDDLE AGED; PATHOLOGY; YOUNG ADULT;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HISTOCYTOCHEMISTRY; HUMANS; INTERLEUKINS; MACROPHAGE ACTIVATION; MALE; MIDDLE AGED; RECEPTORS, CELL SURFACE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84960421954     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12488     Document Type: Article

References (27)

1. Fattovich G, Stroffolini T, Zagni I, Donato F,. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127 (5 Suppl. 1): S35-S50.
2. Lauer GM, Walker BD,. Hepatitis C virus infection. N Engl J Med 2001; 345 (1): 41-52.
3. Klein A, Zhadkewich M, Margolick J, Winkelstein J, Bulkley G,. Quantitative discrimination of hepatic reticuloendothelial clearance and phagocytic killing. J Leukoc Biol 1994; 55 (2): 248-252.
4. Rehermann B,. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med 2013; 19 (7): 859-868.
5. Møller HJ,. Soluble CD163. Scand J Clin Lab Invest 2012; 72 (1): 1-13.
6. Møller HJ, Grønbaek H, Schiødt FV, et al,. Soluble CD163 from activated macrophages predicts mortality in acute liver failure. J Hepatol 2007; 47 (5): 671-676.
7. Ye H, Wang L, Zhao J, Wang K,. Increased CD163 expression is associated with acute-on-chronic hepatitis B liver failure. World J Gastroenterol 2013; 19 (18): 2818-2825.
8. Waidmann O, Brunner F, Herrmann E, Zeuzem S, Piiper A, Kronenberger B,. Macrophage activation is a prognostic parameter for variceal bleeding and overall survival in patients with liver cirrhosis. J Hepatol 2013; 58 (5): 956-961.
9. Waidmann O, Köberle V, Bettinger D, et al,. Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma. J Hepatol 2013; 59 (4): 769-779.
10. Dultz G, Gerber L, Farnik H, et al,. Soluble CD163 is an indicator of liver inflammation and fibrosis in patients chronically infected with the hepatitis B virus. J Viral Hepatitis 2015; 22 (4): 427-432.
11. Kazankov K, Barrera F, Møller HJ, et al,. Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C. Hepatology 2014; 60 (2): 521-530.
12. Heim MH,. Innate immunity and HCV. J Hepatol 2013; 58 (3): 564-574.
13. McFarland AP, Horner SM, Jarret A, et al,. The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat Immunol 2014; 15 (1): 72-79.
14. Sarrazin C, Schwendy S, Möller B, et al,. Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks. Gastroenterology 2011; 141 (5): 1656-1664.
15. Sarrazin C, Susser S, Doehring A, et al,. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 2011; 54 (3): 415-421.
16. Dolganiuc A, Norkina O, Kodys K, et al,. Viral and host factors induce macrophage activation and loss of toll-like receptor tolerance in chronic HCV infection. Gastroenterology 2007; 133 (5): 1627-1636.
17. Andersen ES, Rødgaard-Hansen S, Moessner B, Christensen PB, Møller HJ, Weis N,. Macrophage-related serum biomarkers soluble CD163 (sCD163) and soluble mannose receptor (sMR) to differentiate mild liver fibrosis from cirrhosis in patients with chronic hepatitis C: a pilot study. Eur J Clin Microbiol Infect Dis 2014; 33 (1): 117-122.
18. Shiratori Y, Imazeki F, Moriyama M, et al,. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132 (7): 517-524.
19. Thomas DL, Thio CL, Martin MP, et al,. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461 (7265): 798-801.
20. Honda M, Sakai A, Yamashita T, et al,. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139 (2): 499-509.
21. McGilvray I, Feld JJ, Chen L, et al,. Hepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotype. Gastroenterology 2012; 142 (5): 1122-1131.e1.
22. Noureddin M, Wright EC, Alter HJ, et al,. Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology (Baltimore, MD) 2013; 58 (5): 1548-1557.
23. Sato M, Kondo M, Tateishi R, et al,. Impact of IL28B genetic variation on HCV-induced liver fibrosis, inflammation, and steatosis: a meta-analysis. PLoS One 2014; 9 (3): e91822.
24. Cisneros E, Baños I, Citores MJ, et al,. Increased risk of severe hepatitis C virus recurrence after liver transplantation in patients with a T allele of IL28B rs12979860. Transplantation 2012; 94 (3): 275-280.
25. Duarte-Rojo A, Veldt BJ, Goldstein DD, et al,. The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables. Transplantation 2012; 94 (2): 197-203.
26. Radkowski M, Opoka-Kegler J, Cortes KC, et al,. Evidence for immune activation in patients with residual hepatitis C virus RNA long after successful treatment with IFN and ribavirin. J Gen Virol 2014; 95 (Pt 9): 2004-2009.
27. Pham TNQ, Mercer SE, Michalak TI,. Chronic hepatitis C and persistent occult hepatitis C virus infection are characterized by distinct immune cell cytokine expression profiles. J Viral Hepatitis 2009; 16 (8): 547-556.